KR102053507B1 - 약물 내성 암을 치료하는 방법 - Google Patents

약물 내성 암을 치료하는 방법 Download PDF

Info

Publication number
KR102053507B1
KR102053507B1 KR1020177000067A KR20177000067A KR102053507B1 KR 102053507 B1 KR102053507 B1 KR 102053507B1 KR 1020177000067 A KR1020177000067 A KR 1020177000067A KR 20177000067 A KR20177000067 A KR 20177000067A KR 102053507 B1 KR102053507 B1 KR 102053507B1
Authority
KR
South Korea
Prior art keywords
prochlorperazine
cancer
pharmaceutical composition
group
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177000067A
Other languages
English (en)
Korean (ko)
Other versions
KR20170040183A (ko
Inventor
치-잉 후앙
피터 무-신 창
콴-위 첸
춘-헝 우
타이-샨 청
청-하오 위
Original Assignee
내셔널 양밍 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔널 양밍 유니버시티 filed Critical 내셔널 양밍 유니버시티
Publication of KR20170040183A publication Critical patent/KR20170040183A/ko
Application granted granted Critical
Publication of KR102053507B1 publication Critical patent/KR102053507B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177000067A 2014-06-02 2015-06-02 약물 내성 암을 치료하는 방법 Active KR102053507B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462006630P 2014-06-02 2014-06-02
US62/006,630 2014-06-02
PCT/CN2015/000380 WO2015184794A1 (en) 2014-06-02 2015-06-02 Method for treating drug resistant cancer

Publications (2)

Publication Number Publication Date
KR20170040183A KR20170040183A (ko) 2017-04-12
KR102053507B1 true KR102053507B1 (ko) 2019-12-06

Family

ID=54766042

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000067A Active KR102053507B1 (ko) 2014-06-02 2015-06-02 약물 내성 암을 치료하는 방법

Country Status (10)

Country Link
US (1) US20170105999A1 (https=)
EP (1) EP3148547B1 (https=)
JP (1) JP2017516827A (https=)
KR (1) KR102053507B1 (https=)
CN (1) CN106794184A (https=)
AU (2) AU2015271561A1 (https=)
CA (1) CA2963269A1 (https=)
TW (1) TWI735413B (https=)
WO (1) WO2015184794A1 (https=)
ZA (1) ZA201608820B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250094197A (ko) 2023-12-18 2025-06-25 서울대학교산학협력단 신규 베타-카볼린 유도체 및 이를 포함하는 약물 내성 암 예방 또는 치료용 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695138B1 (en) * 2016-10-17 2017-07-04 Acenda Pharma, Inc. Phenothiazine derivatives and methods of use thereof
US11931366B2 (en) * 2018-04-19 2024-03-19 Washington University Compositions and methods of use thereof for treatment of proteinopathies
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
CN113264903A (zh) * 2021-05-27 2021-08-17 郑州大学 一种吩噻嗪类化合物及其制备方法和应用
WO2025029893A1 (en) * 2023-07-31 2025-02-06 National Yang Ming Chiao Tung University Composition and method of treating a cancer through affecting membrane receptors of cancer cells and their derived extracellular vesicles
CN117959295A (zh) * 2024-02-27 2024-05-03 郑州大学 化合物在制备抗肿瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149186A2 (en) * 2011-04-29 2012-11-01 The Trustees Of The University Of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185243C (zh) 1999-10-26 2005-01-19 中国人民解放军第二军医大学 一种防治心脑血管疾病的四羟基二苯乙烯苷类新化合物
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
AU2006315632A1 (en) * 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
US20100069458A1 (en) * 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
AU2012255920A1 (en) * 2011-05-18 2013-11-07 Merck Sharp & Dohme Corp. Therapeutic anti-IGF1R combinations
WO2013070688A1 (en) * 2011-11-11 2013-05-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
US8809299B2 (en) * 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149186A2 (en) * 2011-04-29 2012-11-01 The Trustees Of The University Of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Chemother Pharmacol., 2000., Vol.46, No.5., pp 403-410*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250094197A (ko) 2023-12-18 2025-06-25 서울대학교산학협력단 신규 베타-카볼린 유도체 및 이를 포함하는 약물 내성 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CN106794184A (zh) 2017-05-31
EP3148547B1 (en) 2024-01-03
TWI735413B (zh) 2021-08-11
ZA201608820B (en) 2019-12-18
US20170105999A1 (en) 2017-04-20
EP3148547C0 (en) 2024-01-03
AU2018222881A1 (en) 2018-09-13
AU2015271561A1 (en) 2017-01-19
CA2963269A1 (en) 2015-12-10
EP3148547A1 (en) 2017-04-05
EP3148547A4 (en) 2018-01-10
KR20170040183A (ko) 2017-04-12
WO2015184794A1 (en) 2015-12-10
JP2017516827A (ja) 2017-06-22
TW201617078A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
KR102053507B1 (ko) 약물 내성 암을 치료하는 방법
US12161607B2 (en) Combination of cannabinoids in the treatment of leukemia
Wang et al. Matrine suppresses NLRP3 inflammasome activation via regulating PTPN2/JNK/SREBP2 pathway in sepsis
ES2962890T3 (es) Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa
ES2881332T3 (es) Ingrediente farmacéutico activo (IFA) que comprende cannabinoides para su uso en el tratamiento del cáncer
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
BR112013028095B1 (pt) Uso de inibidores de csf-1r para o tratamento de tumores cerebrais
JP2018533560A (ja) 癌を治療するための併用療法
US20140294994A1 (en) Pharmaceutical composition for elimination of cancer stem cells
JP2019034977A (ja) 癌を処置するための新規方法
JPWO2015178426A1 (ja) がん幹細胞の増殖抑制剤
JP6462582B2 (ja) がんの治療のための方法および組成物
TWI434680B (zh) 二萜類化合物於治療攝護腺癌之用途
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
KR102732648B1 (ko) 에보디아민을 유효성분으로 포함하는 비소세포폐암의 예방 또는 치료용 약학적 조성물
CN106999525A (zh) 用于治疗间皮瘤的菜蓟滴定提取物
JPWO2015156409A1 (ja) 抗癌剤および副作用軽減剤
KR20200050761A (ko) 다이설피람을 포함하는 항암용 조성물
TWI542348B (zh) 含４－乙醯基－安卓奎諾－ｂ之組合物用於製備抑制癌細胞生長之藥物的用途
WO2023154012A2 (en) Herbal formulations, its method of preparation and its method of use
KR20150083353A (ko) 경요도적 주입용 방광암 예방 또는 치료를 위한 약제학적 조성물
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
CN109303783B (zh) 自噬抑制剂在制备增强石蒜碱抗肝癌活性药物中的应用
KR20200111384A (ko) 파노비노스테트를 포함하는 모야모야병 치료용 약학 조성물
KR102415193B1 (ko) 벤즈브로마론을 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학 조성물

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20170102

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171213

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20181114

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190902

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191202

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220328

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220328

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230630

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240725

Start annual number: 6

End annual number: 6